Carestio Daniel A 4

What Happened Daniel A. Carestio, President, CEO and a director of STERIS plc, received equity awards on June 2, 2026: 23,736 ordinary shares (restricted stock award) and a derivative award of 82,740 shares (an option award). On the same date 2,369 restricted shares vested and 995 of those vested shares were withheld to cover tax withholding obligations; the 995 shares were valued at $209.76 each for a total of $208,711 (disposed to issuer to satisfy taxes). The grants were recorded at $0 cost to the insider (standard for awards).

Key Details

• Transaction date: June 2, 2026; Form 4 filed June 4, 2026 (timely).
• Awards: 23,736 ordinary restricted shares acquired (A); 82,740 derivative award (A) (option).
• Tax withholding: 995 shares withheld/disposed (F) from 2,369 vested shares; withholding price $209.76/sh, total $208,711 (F2).
• Restricted-share schedule (F1): 50,113 shares are restricted as of June 2, 2026, with scheduled lapses across June 2026–2029 per the footnote.
• Option vesting schedule (F3): the 82,740 option units become exercisable in four tranches of 20,685 on June 2, 2027; June 2, 2028; June 4, 2029; and June 3, 2030.
• Shares owned after the transactions: not specified in the material provided.

Context

• The 995-share disposition was a routine tax-withholding to satisfy employment/tax obligations (not an open-market sale by the insider). The issuer determined the withholding value using the NYSE closing price on June 2, 2026.
• The 82,740-unit derivative award is an option grant that vests over multiple future dates (see F3); it is not an immediate sale or exercise.
• Equity awards and option grants are acquisitions but do not necessarily indicate buying sentiment; tax withholding on vested shares is common and administrative.